JP2016104045A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104045A5
JP2016104045A5 JP2016043151A JP2016043151A JP2016104045A5 JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5 JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5
Authority
JP
Japan
Prior art keywords
cell
glycoprotein
seq
protein comprises
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016043151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016104045A (ja
JP6211642B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104045A publication Critical patent/JP2016104045A/ja
Publication of JP2016104045A5 publication Critical patent/JP2016104045A5/ja
Application granted granted Critical
Publication of JP6211642B2 publication Critical patent/JP6211642B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016043151A 2009-06-02 2016-03-07 フコシル化欠損細胞 Expired - Fee Related JP6211642B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US61/183,400 2009-06-02
US34885810P 2010-05-27 2010-05-27
US61/348,858 2010-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014251541A Division JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202634A Division JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Publications (3)

Publication Number Publication Date
JP2016104045A JP2016104045A (ja) 2016-06-09
JP2016104045A5 true JP2016104045A5 (enExample) 2016-12-01
JP6211642B2 JP6211642B2 (ja) 2017-10-11

Family

ID=42338231

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012514045A Expired - Fee Related JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞
JP2016043151A Expired - Fee Related JP6211642B2 (ja) 2009-06-02 2016-03-07 フコシル化欠損細胞
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012514045A Expired - Fee Related JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Country Status (16)

Country Link
US (8) US8409838B2 (enExample)
EP (3) EP3279326B1 (enExample)
JP (4) JP5744856B2 (enExample)
KR (2) KR101641526B1 (enExample)
CN (1) CN102459603B (enExample)
AU (1) AU2010256753B2 (enExample)
BR (1) BRPI1010035A2 (enExample)
CA (1) CA2764370C (enExample)
DK (3) DK3279326T3 (enExample)
ES (2) ES2661074T3 (enExample)
HU (1) HUE038596T2 (enExample)
IL (1) IL216624A (enExample)
PL (3) PL2808393T3 (enExample)
SG (1) SG176251A1 (enExample)
TW (1) TWI513818B (enExample)
WO (1) WO2010141478A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
TWI513818B (zh) 2009-06-02 2015-12-21 Regeneron Pharma 岩藻糖基化(fucosylation)-缺乏之細胞
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
CN106604930B (zh) * 2014-05-30 2021-10-29 新英格兰生物实验室公司 去糖基化试剂和方法
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(一)
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
AU2017206006B2 (en) * 2016-01-06 2019-08-29 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR102906454B1 (ko) * 2016-04-20 2026-01-02 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
SG11202101099PA (en) * 2018-08-29 2021-03-30 United Biopharma Inc Afucosylated antibodies and manufacture thereof
CN113423731B (zh) 2018-10-29 2024-05-14 株式会社免疫生物研究所 抗hiv抗体及其制造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20230017815A (ko) 2020-05-26 2023-02-06 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
AU2021283349A1 (en) 2020-06-03 2023-02-02 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
JP2024527235A (ja) 2021-06-22 2024-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗EGFRvIII抗体薬物コンジュゲート及びその使用
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
KR20240169150A (ko) 2022-03-02 2024-12-02 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 생물반응기

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
PT1914244E (pt) * 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
WO2002031140A1 (en) * 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
JP4323167B2 (ja) 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
MX2007015107A (es) 2005-06-03 2008-02-15 Genentech Inc Metodo para producir anticuerpos con funcion mejorada.
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2679732A1 (en) 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2311864A4 (en) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
TWI513818B (zh) 2009-06-02 2015-12-21 Regeneron Pharma 岩藻糖基化(fucosylation)-缺乏之細胞
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof

Similar Documents

Publication Publication Date Title
JP2016104045A5 (enExample)
AR132934A2 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
MY189819A (en) Genetically modified cells and uses thereof
IL310186B1 (en) Plasma kallikrein binding proteins
HK1218297A1 (zh) 用於生产单克隆抗体的改进方法
JP2017505620A5 (enExample)
MX366647B (es) Cambio de temperatura para una expresión con mayor rendimiento de polipéptidos en levaduras y otras células transformadas.
GB201003701D0 (en) System for the expression of a protein
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
JP2015532096A5 (enExample)
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA202091349A1 (ru) Способы культивирования клеток
RU2015129656A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
BR112016028538A2 (pt) processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
ZA202100384B (en) Influenza virus hemagglutinin mutants
MX2019007924A (es) Vacunas contra la influenza.
BR112016023980A2 (pt) anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)
JP2016512251A5 (enExample)
JP2015536347A5 (enExample)
SG11201902998SA (en) PROMOTER OF Hspa5 GENE
BR112017017303B8 (pt) Método para obtenção de clones de células de alta produtividade